Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Treatment Outcome. Found 200 abstracts

no pagination
Dash PK, Kaminski R, Bella R, Su H, Mathews S, Ahooyi TM, Chen C, Mancuso P, Sariyer R, Ferrante P, Donadoni M, Robinson JA, Sillman B, Lin Z, Hilaire JR, Banoub M, Elango M, Gautam N, Mosley RL, Poluektova LY, McMillan J, Bade AN, Gorantla S, Sariyer IK, Burdo TH, Young WB, Amini S, Gordon J, Jacobson JM, Edagwa B, Khalili K, Gendelman HE. Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice. Nat Commun. 2019 Jul 02;10(1):2753.   PMCID: PMC6606613
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet (London, England). 2019 Jan 05;393(10166):40-50.   PMCID: PMC6541928
Chhatre S, Jefferson A, Cook R, Meeker CR, Kim JH, Hartz KM, Wong YN, Caruso A, Newman DK, Morales KH, Jayadevappa R. Patient-centered recruitment and retention for a randomized controlled study. Trials. 2018 Mar 27;19(1):205.   PMCID: PMC5870194
Edwards DC, Cahn DB, Smaldone MC, Kutikov A. Use of administrative data for comparative effectiveness research in the treatment of non-prostate genitourinary malignancies. Urol Oncol. 2018 Apr;36(4):193-212.
Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 Feb;36(4):376-82.   PMCID: PMC5805480
Joshi SS, Handorf EA, Zibelman M, Plimack ER, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. Eur Urol. 2018 Sep;74(3):387-93.
Jung K, Park JC, Kang H, Brandes JC. Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer. Epidemiology and health. 2018 Aug;40:e2018040.   PMCID: PMC6232654
Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger CS, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O'Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ. Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018 Jun;21(6):742-7.
Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger CS, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O'Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ. Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. Value Health. 2018 Jun;21(6):742-7.
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 Apr 10;36(11):1080-7.   PMCID: PMC5891129
Zuniga S, Ebersole B, Jamal N. Improved swallow outcomes after injection laryngoplasty in unilateral vocal fold immobility. Ear Nose Throat J. 2018 Aug;97(8):250-6.
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-92.
Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr;123(7):1259-71.   PMCID: PMC5705038
Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol. 2017 Aug;40(4):393-8.   PMCID: PMC5026539
Chambers SK, Occhipinti S, Foley E, Clutton S, Legg M, Berry M, Stockler MR, Frydenberg M, Gardiner RA, Lepore SJ, Davis ID, Smith DP. Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial. J Clin Oncol. 2017 Jan 20;35(3):291-7.
Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017 Nov 15;123(22):4411-8.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, Decamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2017 Apr;15(4):504-35.
Fan F, Yuan Z, Qin X, Li J, Zhang Y, Li Y, Yu T, Ji M, Ge J, Zheng M, Yang X, Bao H, Cheng X, Gu D, Zhao D, Wang J, Sun N, Chen Y, Wang H, Wang X, Parati G, Hou F, Xu X, Wang X, Zhao G, Huo Y. Optimal Systolic Blood Pressure Levels for Primary Prevention of Stroke in General Hypertensive Adults: Findings From the CSPPT (China Stroke Primary Prevention Trial). Hypertension (Dallas, Tex : 1979). 2017 Apr;69(4):697-704.
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhaeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crino L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WE. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10;35(35):3924-33.   PMCID: PMC6075826
Ito T, Derweesh IH, Ginzburg S, Abbosh PH, Raheem OA, Mirheydar H, Hamilton Z, Chen DY, Smaldone MC, Greenberg RE, Viterbo R, Kutikov A, Uzzo RG. Perioperative Outcomes Following Partial Nephrectomy Performed on Patients Remaining on Antiplatelet Therapy. J Urol. 2017 Jan;197(1):31-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Treatment Outcome

Treatment Outcome therapy Male Aged Middle Aged therapeutic use adverse effects drug therapy pathology mortality United States administration & dosage Female methods etiology Time Factors Retrospective Studies prevention & control diagnosis Adult Antineoplastic Combined Chemotherapy Protocols Antineoplastic Agents Prostatic Neoplasms Combined Modality Therapy epidemiology statistics & numerical data surgery 80 and over Aged Androgen Antagonists Neoplasm Metastasis complications physiology Lung Neoplasms Molecular Targeted Therapy Risk Factors Registries Prognosis Survival Rate tolerability Renal Cell Carcinoma psychology Kaplan-Meier Estimate Surveys and Questionnaires Monoclonal Antibodies immunology Comparative Effectiveness Research Neoplasm Staging Immunotherapy Recurrence Non-Small-Cell Lung Carcinoma Attitudes Health Knowledge-Practice drug safety Clinical Trials as Topic oncology Medical Oncology genetics Hormone-Dependent Neoplasms Drug-Related Side Effects and Adverse Reactions Follow-Up Studies Neoplasms Patient Selection Critical Pathways patient-reported outcomes physiopathology Disease-Free Survival Drug Administration Schedule Drug Dose-Response Relationship Patient Reported Outcome Measures United States Food and Drug Administration Kidney Neoplasms Docetaxel virology Pro-ctcae Cisplatin head and neck cancer Transitional Cell Carcinoma Patient Readmission High-Volume Hospitals non-Hodgkin lymphoma Cost of Illness HIV-1 Remote Consultation Veterans Mindfulness Salvage Therapy Hematopoietic Stem Cell Transplantation Taxoids Incidence Piperidines Renal cell carcinoma Patient Dropouts Young Adult Datasets as Topic Randomized Controlled Trials as Topic Paclitaxel Intensity-Modulated Radiotherapy Prospective Studies Primary Prevention Patient Education as Topic Anti-HIV Agents drug effects Viral DNA Psychological Adaptation Perioperative Period goal blood pressure myc Genes Cancer survival Group Psychotherapy Oral Administration Adenocarcinoma Vocal Cord Paralysis Double-Blind Method Combination Drug Therapy hemorrhage hematopoietic cell transplantation (HCT) Papillomavirus Infections Quinazolines Blood Transfusion human papillomavirus Fluorouracil Neoplasm Drug Resistance Internationality stroke Gene Editing carcinoma diffuse large B-cell lymphoma (DLBCL) National Cancer Institute (US) Androgen antagonists nephrectomy Stroke Biomarkers Carboplatin Surgical Blood Loss Nephrectomy Quality of Life Angiotensin-Converting Enzyme Inhibitors Cetuximab Deglutition Comparative effectiveness research Monoclonal Antibodies-Humanized Single-Blind Method Hypertension Large B-Cell Lymphoma-Diffuse Hormones Neoplasm Invasiveness clopidogrel Cognitive Therapy secondary Prostate-Specific Antigen Genetic Translocation
Last updated on Friday, December 06, 2019